2 Information about lenvatinib

Marketing authorisation

2.1 Lenvatinib (Kisplyx, Eisai) is indicated 'in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy'.

Dosage in the marketing authorisation

2.2 The recommended daily dose of lenvatinib is 18 mg (1×10 mg capsule and 2×4 mg capsules) once daily, with 5 mg of everolimus once daily.


2.3 The list price of lenvatinib is £1,437.00 per 30‑capsule pack (4 mg and 10 mg). The list price of everolimus is £2,250.00 per 30‑tablet pack of 5 mg everolimus. The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of lenvatinib, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.

  • National Institute for Health and Care Excellence (NICE)